HSV2 gD Specific Neutra™ Antibody Products

Are you currently facing challenges in serotype-specific detection or the risk of antibody-dependent enhancement (ADE) in your dengue research? Our HSV2 gD Specific Neutra™ Antibody Products: Shielding Your Research Against Viral Entry! Are you currently facing high background noise in viral assays, low neutralization potency in candidate screening, or challenges in mapping the complex fusion machinery of Herpes Simplex Virus? Our HSV2 gD Specific Neutra™ Antibody Products help you achieve definitive viral inhibition, precise epitope characterization, and accelerated therapeutic benchmarking through high-affinity binding to glycoprotein D, the master key of HSV-2 cellular entry.

Introduction of HSV2 gD

Herpes Simplex Virus Type 2 (HSV-2) remains a global health burden, primarily causing genital herpes and significantly increasing the risk of HIV-1 acquisition. Central to its pathogenesis is Glycoprotein D (gD), a structural component of the viral envelope that serves as the primary receptor-binding protein.

Structure and Function

The gD molecule consists of an N-terminal signaling domain and a C-terminal extension that wraps around the core. In its "closed" state, the C-terminus obscures the N-terminal loop. Upon binding to cellular receptors, specifically Herpesvirus Entry Mediator (HVEM) or Nectin-1, gD undergoes a dramatic conformational change. This "unmasking" event triggers a signal transduction cascade to the gH/gL complex, which eventually activates the fusogen gB to merge the viral and host membranes.

Structure and Function

The gD is the primary attachment protein that determines host cell tropism. It binds to receptors such as HVEM, Nectin-1, or 3-O-sulfated heparan sulfate. Upon binding, gD undergoes a conformational change that triggers the activation of gH/gL, initiating membrane fusion. This interaction also activates the NF-κB and PI3K/Akt pathways, promoting cell survival and inflammatory responses. Furthermore, gD binding to HVEM can interfere with BTLA signaling, effectively modulating the host's immune response to facilitate viral persistence.

Clinical Impact and Disease

The interaction between gD and HVEM is not merely structural; literature suggests it may modulate the host's innate immune response by dampening local chemokine production. Clinically, gD is the most immunogenic protein on the virion, making it the primary target for neutralizing antibodies. Its role in viral "surfing" along filopodia and subsequent cell-to-cell spread makes it a focal point for preventing both primary infection and the reactivation of latent virus in sensory neurons.

Fig.1 Illustration of pathogenesis and immune responses of HSV-2 in vaccine development.¹

Applications of anti HSV2 gD Neutralizing Antibodies

Neutralizing antibodies targeting gD are indispensable across several biological and clinical domains:

• Viral Entry Inhibition Studies: They are used to dissect the entry mechanisms of clinical HSV-2 isolates, helping researchers understand tissue tropism (e.g., epithelial vs. neuronal entry).
• Vaccine Development: Anti-gD titers serve as a critical correlate of protection in preclinical vaccine trials. Neutralizing antibodies help validate that vaccine-induced responses effectively target "vulnerable" epitopes.
• Passive Immunotherapy Research: Investigating the potential of monoclonal antibodies (mAbs) as prophylactic agents, particularly in preventing neonatal herpes or reducing viral shedding in seropositive individuals.
• Assay Standardization: Providing reliable controls for Microneutralization (MN) assays and Plaque Reduction Neutralization Tests (PRNT).

Our anti HSV2 gD Neutralizing Antibodies

Creative Biolabs provides an elite portfolio of HSV2 gD Specific Neutra™ Antibodies characterized by exceptional binding kinetics and biological activity. Our collection includes:

• High-Potency Neutralizers: Clones specifically selected for their ability to abrogate syncytia formation and cell-to-cell spread at sub-nanomolar concentrations.
• Receptor-Specific Blockers: Antibodies that selectively inhibit gD-HVEM or gD-Nectin-1 interactions, allowing for the study of receptor-specific pathogenesis.
• Multi-Platform Compatibility: Each antibody is rigorously validated for use in Western Blot (WB), Immunofluorescence (IF), and Flow Cytometry, ensuring seamless integration into your existing workflow.
• Custom Conjugation Services: Available with various fluorophores or biotinylation to support high-throughput screening and advanced imaging.

Creative Biolabs is dedicated to providing the biopharmaceutical industry with high-quality HSV-2 research tools. From recombinant gD proteins to our flagship Neutra™ antibody line, we empower your team to overcome technical hurdles in drug discovery and virology research.

Contact Our Team for More Information and to Discuss Your Project.

Reference

1. Zhu, Xiao-Peng et al. "HSV-2 vaccine: current status and insight into factors for developing an efficient vaccine." Viruses vol. 6,2 371-90. 24 Jan. 2014, Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.3390/v6020371